Dr. Estela Rodriguez
@Latinamd
Followers
8K
Following
18K
Media
5K
Statuses
13K
Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
Perhaps our most important publication in public health related to cancer this year. Led by @Jani_Chinmay - our chief fellow and soon to be colleague @SylvesterCancer This was his oral presentation at #ASCO25 @ASCO and got a lot of interest Alcohol-related cancer deaths are
0
3
5
Mourning the loss of @anguspratt, a lung cancer 🫁 patient advocate from @LungCancer_Can, whose work continues to inspire us to aim higher and fight for better services and treatments for people with #lungcancer worldwide. Your light — and your red-beanie spirit — lives on. 🙏
0
0
1
How can we better support the growing community of lung cancer survivors? Dr. Stacy Wentworth and an inspiring panel are exploring what survivorship looks like today—and how to strengthen support systems for those living with and beyond lung cancer. #NLCRT2025
0
1
3
APOL1 Genetic Testing at No Cost to Patients! Are you incorporating APOL1 genetic testing into your workflow? Discover No-Cost APOL1 Genotyping Program for eligible patients sponsored by Vertex Pharmaceuticals. Learn more today!
17
35
206
Our CMO @jrgralow discussed the importance of insurance coverage of fertility preservation for cancer patients with @thecancerletter. Access the article https://t.co/FSGpiJI0VB and see ASCO's updated guidelines: https://t.co/PNxdv7tIKv
#ASCOadvocacy
2
6
11
NIH shut out hundreds of young scientists from funding to start their own labs https://t.co/zgz6OSujya via @statnews
statnews.com
Special Report: The NIH has shut out hundreds of young scientists from funding to start their own labs.
0
0
2
2025 is coming to an end. Sharing some of the more exciting contributions we made this year. We presented the first prospective multicenter study showing that adding ctRNA to ctDNA significantly boosts the detection of actionable biomarkers in liquid biopsy for metastatic #NSCLC.
0
8
13
2025 is coming to an end. We were privileged this year to make a number of contributions that help people living with cancer live longer and better lives. First one - I was honored to present the five-year update from the ARROW study which established pralsetinib as one of the
1
5
20
Don’t miss the last @TumorBoardTues of this year on ADCs in #lungcancer with @ADesaiMD @SanadAlhushki 👇👇#lcsm
#TumorBoardTuesday 💊Antibody-drug conjugates have been providing hope for several cancer types 📢Join us Tuesday, 12-09-25 at 8PM ET as @ADesaiMD & @SanadAlhushki🗣️the use of Teliso-V (🎯cMET) and T-DXd (🎯HER2) for 2nd Line #NSCLC RT and bring others into the discussion‼️
0
3
11
#ESMOAsia2025 Lung Orals🔥 MARIPOSA: Asian subgroup analysis @rinrin_1969 - HR OS 0.74 - majority of MARIPOSA made up of asian subset - similar tox signal, & crossing of curves at 9m #ESMOAmbassadors @myesmo @OncoAlert #LCSM
2
17
37
2026 Medical Oncology In-Training Exam registration is open! This proctored, Internet-based exam (Feb 24 & 25) is a great way to track progress w/ teaching points & performance percentages across key domains. Discounts available. Learn more & register: https://t.co/vhDXwhuMEx
0
4
7
🏰 The Lord Marshal summons you on this first day of Christmas! Enter daily for a chance to win two tickets to the Castle. Ten champions will be chosen—could it be you? Click the link in our bio to enter!
1
7
66
Grateful to present an update on the phase II eNRGy trial at #NACLC25: zenocutuzumab in pts with treatment-naive, NRG1-fusion positive NSCLC. Zenocutuzumab was FDA approved December 2024 in previously treated NSCLC and pancreatic cancer but did include some treatment naive.
4
9
38
A new wave of targeted therapies and gentler chemotherapy options is improving survival and expanding the possibility of cure for older adults newly diagnosed with acute myeloid leukemia (AML). The updated 2025 @ASH_hematology AML treatment guidelines, led by Sylvester’s Dr.
0
7
27
Dr. Justin Watts (@JustinWattsMD) will join experts at #ASH25 to discuss the latest evidence from clinical trials for new and emerging menin inhibitors for #AML. Topics will include: KMT2A & NPM1 biology, guideline‑supported use, dosing/administration, transplant strategy,
0
5
10
Dr. Benjamin Diamond (@BenDiamondMD) will present new findings from the ReKInDLE study at #ASH25, presenting a potential path forward for early relapse/refractory #MultipleMyeloma patients. Learn more about our presence: https://t.co/FndtbHJoUV.
1
8
13
This Wednesday: We're chatting with former STRATO team member & SuperRare founder John Crain! 🚀 Let’s dive into the future of NFTs and where they're going next. Plus, don’t miss our breakdown of the new STRATO Rewards program earlier in the segment!
2
1
7
Love this story of Drs @d_bayik and her husband and scientific collaborator @DionysiosWatson (who is also our Thoracic Translational Lead) working together @SylvesterCancer
The couple that advances scientific discovery together, stays together 🧠💞 Dr. Defne Bayik (@d_bayik) and her husband, Dr. Dionysios Watson (@DionysiosWatson), are teaming up to take on one of the most lethal adult brain tumors: glioblastoma. Their innovative strategy enlists
0
2
10
New episode of the @IASLC podcast, Lung Cancer Considered, reviews some new antibody drug conjugates (ADCs) for EGFR mutant NSCLC including datopotamab deruxtecan (Dato-DXd) and sacituzumab tirumotecan (Sac-TMT) with Drs. @ElaineShumMD and Li Zhang. https://t.co/SViOHjSjer
iaslc.org
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugat ...
0
12
38
Look at the snow bird ❄️ that came to visit us in Florida last night. Great welcoming @JSabari @nyulangone for a night of learning about sequencing of #EGFR #lungcancer therapies with @LuisRaezMD @EddieSantosMD #lcsm
0
1
19
Results from amivantamab + lazertinib in atypical EGFR mutant NSCLC from CHRYSALIS-2 (cohort C) @JCO_ASCO (n=105). RR 52%, DOR 14.1m, PFS 11.1m and as first-line, RR 57%, DOR 20.7m, PFS 19.5m. Similar RR for solitary vs compound. In PACC mt, RR 45%. https://t.co/vBPTbhklFM
ascopubs.org
PURPOSEFor patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment...
0
29
81
Last week, our @HemOncMiami fellows led a fantastic Grand Debates-style Journal club on front-line EGFR-mutated NSCLC: MARIPOSA vs FLAURA2. Amazing work by @AksheeBatra and @d_tuerff, bringing sharp insight into how the field continues to shift! 🔥📘🫁 @SylvesterCancer @GlopesMd
0
7
19
building or investing in ai + btc? join the weekly aibtc community call an open format x space for: · showcasing projects and research · meeting collaborators · finding new opportunities weekly links posted in thread 👇
4
9
18